BiotechTube

Metformin + Placebo

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Metabolic Complications

Conditions

Metabolic Complications

Trial Timeline

Aug 1, 2007 → Aug 1, 2011

NCT ID
NCT00682448

About Metformin + Placebo

Metformin + Placebo is a approved stage product being developed by Eli Lilly for Metabolic Complications. The current trial status is completed. This product is registered under clinical trial identifier NCT00682448. Target conditions include Metabolic Complications.

What happened to similar drugs?

18 of 20 similar drugs in Metabolic Complications were approved

Approved (18) Terminated (4) Active (2)
✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
✅Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
✅Rosuvastatin + AtorvastatinAstraZenecaApproved
✅rosuvastatinAstraZenecaApproved
✅Simvastatin + Simvastatin/EzetimibeMerckApproved
✅Simvastatin + Vytorin + Placebo + EzetimibeMerckApproved
✅simvastatin + ezetimibe/simvastatinMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00682448ApprovedCompleted

Competing Products

20 competing products in Metabolic Complications

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
35
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
40
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
40
14C-labeled YM178Astellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
LY518674Eli LillyPhase 2
35
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
47
Tirzepatide + SemaglutideEli LillyPre-clinical
18
LY3849891 + PlaceboEli LillyPhase 1
33
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
50
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaApproved
43
AZD2693 + PlaceboAstraZenecaPhase 1
29
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40
rosuvastatinAstraZenecaApproved
43
EfinopegdutideMerckPhase 2
35
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
27
Vericiguat + PlaceboMerckPhase 2
35
MetforminMerckPhase 2
35